ADMA Biologics ADMA Other liabilities
Other liabilities at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's other liabilities?
- ADMA Biologics (ADMA) reported other liabilities of -$340K in Q1 2026.
- How has ADMA Biologics's other liabilities changed year-over-year?
- ADMA Biologics's other liabilities increased by 47.7% year-over-year, from -$650K to -$340K.
- What is the long-term trend for ADMA Biologics's other liabilities?
- Over 4 years (2021 to 2025), ADMA Biologics's other liabilities has grown at a 55.5% compound annual growth rate (CAGR), from $219K to -$1.28M.
- What does other liabilities mean?
- Reflects the net change in miscellaneous short-term operating obligations not captured in standard payables or accruals. It helps investors track the movement of secondary operational commitments that impact working capital.